JHVEPhoto Overview I've always preferred to invest with a data-driven long term outlook. Therefore, I look for quality opportunities where I can grow my income and capture a superior total return. With some entities, where you start an initial position really matters most. I think the price level of Pfizer (NYSE:PFE) is one of these opportunities based on the dividend coverage and growth, valuation metrics, and future growth outlook. The current price under $30/share offers an opportunity to lock in potenti ...

Drugmakers including Pfizer, Sanofi and Takeda Pharmaceutical plan to raise prices in the US on more than 500 drugs in early January, according to data analyzed by healthcare research firm 3 Axis Advisors.Excluding different doses and formulations, more than 140 brands of drugs will have their prices raised next month, the data showed.The expected price hikes come as the pharmaceutical industry gears up for the Biden Administration to publish significantly discounted prices for 10 high-cost drugs in Septem ...

You might call it a "Pfizzle."In late 2021, Pfizer (PFE 0.70%) stock was at an all-time high. The company had pulled off a near miracle with its rapid development of a COVID-19 vaccine.It followed that success with the launch of an effective oral COVID pill. Both became megablockbusters, with the vaccine (Comirnaty) generating global sales of $37.8 billion and the antiviral therapy (Paxlovid) raking in an additional $18.9 billion in 2022. It's a much different story today. Pfizer has lost more than half of ...

Michael M. Santiago Pfizer (NYSE:PFE) is a blue chip dividend stock whose medications, product candidates, and vaccines play one of the key roles in the fight against various types of cancer, viruses, immuno-inflammatory, infectious, cardiovascular, and rare diseases. Thesis Since the end of December 2021, Pfizer's share price has fallen more than 54%, reaching a strong support level. This decline can be attributed to the sharp drop in demand for its COVID-19 vaccine, investor concerns about losing exclusiv ...

Pfizer (PFE 0.32%) stock has been in the dumps this year. It is struggling due to declining demand for its COVID products. And it may take some years before its top line starts rising meaningfully again. The company's recent forecast didn't help matters, either. But with the stock losing close to half its value this year, are investors being overly punitive on what's still a top healthcare company?Pfizer's top line may decline in 2024On Dec. 13, Pfizer unveiled its forecast for the coming year, and to say i ...

Key PointsPfizer faced a challenging 2023, marked by a significant 41.84% decline in its stock value as revenue for COVID-19 drugs fell faster than expected. The company anticipates full-year 2024 revenue to fall within the range of $58.5 to $61.5 billion, disappointing investors and analysts.The company's focus on acquisitions is slowing, and Pfizer is returning its focus to dividend increases and share buybacks.5 stocks we like better than PfizerInvestors who own Pfizer Inc. NYSE: PFE may have expected 20 ...

Pfizer Inc. (NYSE:PFE) 6th Annual Evercore ISI HealthCONx Conference November 28, 2023 10:50 AM ET Company Participants Dave Denton - CFO and EVP Conference Call Participants Umer Raffat - Evercore ISI Dave Denton Okay. Great. Umer Raffat Excellent. Well, listen, thank you guys for being here. I think my mic's on. Jazz just put out an update as you guys probably heard. So I don't think Pfizer has a major new update on anything safety? Dave Denton We do not. Umer Raffat Okay. All right. Let's get that out of ...

Pfizer Inc. (NYSE:PFE) Truist Securities BioPharma Symposium November 9, 2023 12:35 PM ET Company Participants Aamir Malik - Executive Vice President and Chief Business Innovation Officer Conference Call Participants Robyn Karnauskas - Truist Securities Robyn Karnauskas Good afternoon. Thanks so much for joining us. I'm Robyn Karnauskas, one of the biotech analysts at Truist. I'm so excited to have for a keynote this afternoon from Pfizer, Aamir Malik, the Chief Business Innovation Officer and Executive Vic ...

Pfizer Inc. (NYSE:PFE) Q3 2023 Results Earnings Conference Call October 31, 2023 10:00 AM ET Company Participants Francesca DeMartino - Chief Investor Relations Officer Albert Bourla - Chairman and Chief Executive Officer Dave Denton - Chief Financial Officer and Executive Vice President Mikael Dolsten - Chief Scientific Officer, President, Pfizer Research & Development Angela Hwang - Chief Commercial Officer, President, Global Biopharmaceuticals Business Chris Boshoff - Chief Oncology Research and Developm ...

Third Quarter 2023 Earnings Teleconference October 31, 2023 ...